BRCA1 and ovarian carcinoma: Their efficacy in the treatment of several different types of cancers is currently being tested in a large number of clinical trials, but their current indication is as fourth line therapy of primarily ovarian cancers in patients with BRCA1/2 mutations who have responded to platinum treatment.